Role of Immunotherapy Agents Grows in Metastatic Colorectal Cancer

Jason Harris
Published: Friday, Jan 10, 2020
Howard S. Hochster, MD, a Distinguished Professor of Medicine, Rutgers Robert Wood Johnson Medical School, Seattle Cancer Care Alliance

Howard S. Hochster, MD

The standard of care in the second line for patients with mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC) has shifted to favor therapy utilizing immunotherapeutic agents, according to Howard Hochster, MD.


Table. (Click to Enlarge)

In the 3-arm COMMIT trial (NCT02997228), investigators are comparing atezolizumab alone versus a modified FOLFOX regimen (folinic acid, fluorouracil, and oxaliplatin; mFOLFOX6) plus bevacizumab (Avastin) with or without atezolizumab for patients with MSI-H mCRC in the frontline setting. Investigators in the ATOMIC trial (NCT02912559) will compare mFOLFOX plus 25 cycles of atezolizumab versus mFOLFOX alone for patients with stage III dMMR CRC in the adjuvant setting.

In the POLEM trial (NCT03827044), patients who have undergone radical surgical resection for stage III dMMR or POLE exonuclease domain–mutant colon cancer will be assigned to chemotherapy with CAPOX (capecitabine and oxaliplatin) for 12 weeks, capecitabine for 24 weeks, or chemotherapy followed by avelumab for 24 weeks.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication